Cargando…
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells
FK866 is a specific inhibitor of NAMPT and induces apoptosis of leukemic cells by depletion of intracellular NAD(+). Since up-regulation of NAMPT is associated with several cases of cancers, including leukemias, we asked whether in leukemic cells inhibition of NAMPT involves p53 pathway. We observed...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Subscription Services, Inc., A Wiley Company
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562481/ https://www.ncbi.nlm.nih.gov/pubmed/22815158 http://dx.doi.org/10.1002/ijc.27726 |
_version_ | 1782258092402016256 |
---|---|
author | Thakur, Basant Kumar Dittrich, Tino Chandra, Prakash Becker, Annette Kuehnau, Wolfgang Klusmann, Jan-Henning Reinhardt, Dirk Welte, Karl |
author_facet | Thakur, Basant Kumar Dittrich, Tino Chandra, Prakash Becker, Annette Kuehnau, Wolfgang Klusmann, Jan-Henning Reinhardt, Dirk Welte, Karl |
author_sort | Thakur, Basant Kumar |
collection | PubMed |
description | FK866 is a specific inhibitor of NAMPT and induces apoptosis of leukemic cells by depletion of intracellular NAD(+). Since up-regulation of NAMPT is associated with several cases of cancers, including leukemias, we asked whether in leukemic cells inhibition of NAMPT involves p53 pathway. We observed that FK866 induced apoptosis and reduced cell proliferation in NB-4, OCI-AML3 and MOLM-13 cell lines. In contrast, the leukemia cell lines, K-562 and Kasumi, containing nonfunctional p53 were relatively unaffected by FK866 treatment. Importantly, direct inhibition of sirtuins significantly reduced the viability of NB-4, OCI-AML3 and MOLM-13 cell lines. Activation of p53 by FK866 involved increased acetylation of p53 at lysine 382 with subsequent increase in the expression of p21 and BAX. Further, knockdown of p53 attenuated the effects of FK866 on apoptosis and cell cycle arrest, which was partly associated with decreased expression of p21 and BAX. Our results suggest the role of p53 acetylation pathway in the anti-leukemic effect of FK866. |
format | Online Article Text |
id | pubmed-3562481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Wiley Subscription Services, Inc., A Wiley Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-35624812013-02-07 Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells Thakur, Basant Kumar Dittrich, Tino Chandra, Prakash Becker, Annette Kuehnau, Wolfgang Klusmann, Jan-Henning Reinhardt, Dirk Welte, Karl Int J Cancer Carcinogenesis FK866 is a specific inhibitor of NAMPT and induces apoptosis of leukemic cells by depletion of intracellular NAD(+). Since up-regulation of NAMPT is associated with several cases of cancers, including leukemias, we asked whether in leukemic cells inhibition of NAMPT involves p53 pathway. We observed that FK866 induced apoptosis and reduced cell proliferation in NB-4, OCI-AML3 and MOLM-13 cell lines. In contrast, the leukemia cell lines, K-562 and Kasumi, containing nonfunctional p53 were relatively unaffected by FK866 treatment. Importantly, direct inhibition of sirtuins significantly reduced the viability of NB-4, OCI-AML3 and MOLM-13 cell lines. Activation of p53 by FK866 involved increased acetylation of p53 at lysine 382 with subsequent increase in the expression of p21 and BAX. Further, knockdown of p53 attenuated the effects of FK866 on apoptosis and cell cycle arrest, which was partly associated with decreased expression of p21 and BAX. Our results suggest the role of p53 acetylation pathway in the anti-leukemic effect of FK866. Wiley Subscription Services, Inc., A Wiley Company 2013-02-15 2012-07-20 /pmc/articles/PMC3562481/ /pubmed/22815158 http://dx.doi.org/10.1002/ijc.27726 Text en Copyright © 2012 UICC http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Carcinogenesis Thakur, Basant Kumar Dittrich, Tino Chandra, Prakash Becker, Annette Kuehnau, Wolfgang Klusmann, Jan-Henning Reinhardt, Dirk Welte, Karl Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells |
title | Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells |
title_full | Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells |
title_fullStr | Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells |
title_full_unstemmed | Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells |
title_short | Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells |
title_sort | involvement of p53 in the cytotoxic activity of the nampt inhibitor fk866 in myeloid leukemic cells |
topic | Carcinogenesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562481/ https://www.ncbi.nlm.nih.gov/pubmed/22815158 http://dx.doi.org/10.1002/ijc.27726 |
work_keys_str_mv | AT thakurbasantkumar involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells AT dittrichtino involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells AT chandraprakash involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells AT beckerannette involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells AT kuehnauwolfgang involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells AT klusmannjanhenning involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells AT reinhardtdirk involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells AT weltekarl involvementofp53inthecytotoxicactivityofthenamptinhibitorfk866inmyeloidleukemiccells |